denkapparat Operations GmbH Acquires Shares of 2,288 Zoetis Inc. (NYSE:ZTS)

denkapparat Operations GmbH bought a new position in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, Holdings Channel.com reports. The firm bought 2,288 shares of the company’s stock, valued at approximately $373,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dunhill Financial LLC increased its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the period. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. raised its position in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new stake in Zoetis in the fourth quarter valued at $44,000. Finally, Quarry LP boosted its position in shares of Zoetis by 45.9% during the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after purchasing an additional 96 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on ZTS. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Piper Sandler upped their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $215.90.

Zoetis Stock Performance

NYSE:ZTS opened at $165.12 on Friday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.33. The firm has a 50 day simple moving average of $166.46 and a 200-day simple moving average of $174.87. The firm has a market cap of $73.94 billion, a PE ratio of 30.19, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.21%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Activity

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock valued at $312,254 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.